Helsinn and Mundipharma China Pharmaceutical jointly announce NMPA’s approval of the oral formulation of Akynzeo® in China

    NEXT STORY
    Roche ranked as one of the most sustainable healthcare companies in the Dow Jones Sustainability Indices for the eleventh year running
    PREV STORY
    Lundbeck to acquire Alder BioPharmaceuticals – a company committed to transforming migraine treatment and prevention – in a transaction valued at up to USD 1.95 billion net of cash
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

    - Baxdela offers a new option for treatment of adult patients with acute bacterial ...

    author_avatar
    NASDAQ Market News

    Revive Therapeutics Partners with Complete Phytochemical Solutions to Advance Research Initiatives for Psilocybin-Based Pharmaceutical Products

    author_avatar
    NASDAQ Market News

    Agios Announces Clinical Proof-of-Concept Has Been Established in Phase 1 Study of Mitapivat, First-in Class PKR Activator, in Sickle Cell Disease

    author_avatar
    NASDAQ Market News